Delivery Order SPE2DB22D2007-SPE2DB26FH6NG
- Not listed
- The Defense Logistics Agency awarded a $12,889.64 delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of October 28, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $2,418.33 for 90 tablets of Losartan-HCTZ 50-12.5 mg, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $18,928.44 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $20,421.45 delivery order to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count) on October 30, 2025, with an ultimate completion date of October 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a single delivery transaction under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets in a quantity of 90 units, with a firm fixed price ceiling value of $1,620.32. This is a non-set-aside, competitively awarded contract with an ultimate completion date of September 29, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a delivery order under a larger contract...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a competitive delivery order valued at $2,430.48 by the Defense Logistics Agency on September 8, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count packages). The contract carries a firm fixed price structure with an ultimate completion date of September 9, 2025, and represents a non-set-aside award. This delivery order falls under AmerisourceBergen's substantial Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $6,254.42 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets in a 90-count quantity. The contract, which is non-set-aside and competitively awarded, is scheduled for completion by October 29, 2025, with performance to be executed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,241.86 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a pharmaceutical supply transaction under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,456.18 delivery order on August 14, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count). This competitive award utilized firm fixed price contracting with no set-aside designation and an ultimate completion date of August 15, 2025. The product will be delivered to the company's headquarters location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets in a 90-count quantity. This firm fixed-price delivery order, valued at $19,522.44, represents a non-competitive, non-set-aside award with an ultimate completion date of November 4, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. This...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB26FH6NGDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,152.20 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count units). This competitively awarded, non-set-aside contract utilizes firm fixed pricing and was issued on October 28, 2025, with an ultimate completion date of October 29, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order functions as a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026 that supports pharmaceutical supply needs across military and federal healthcare systems globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement through its comprehensive pharmaceutical and medical supply portfolio. The company's extensive contract history with DLA demonstrates its capability to fulfill diverse federal healthcare requirements, including brand-name and generic medications across multiple therapeutic domains. The SPE2DX vehicle under which this delivery order was issued represents a strategic sourcing approach that enables AmerisourceBergen to supply military healthcare programs, the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems with flexible and responsive pharmaceutical support worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.2k | 10/28/25 |